Johnson & Johnson Family of Companies
NEWS
With the Omicron surge waning, at least in the U.S., there is speculation that the COVID-19 pandemic may be in its end stages. Some experts, however, warn that this could be premature.
Although the Omicron surge appears to be waning in the U.S., the World Health Organization keeps an eye on four Omicron subvariants.
Teva Pharmaceuticals reported solid earnings for the full year of 2021, posting $15.9 billion in revenues alongside gains of $4.1 billion from the fourth quarter alone.
Johnson & Johnson has temporarily paused production of its COVID-19 vaccine at its manufacturing site in The Netherlands.
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
JOBS
IN THE PRESS